Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

Early research funded by CTF has led to breakthroughs in schwannomatosis research

By August 23, 2017December 18th, 2023Publications, Science & Research, SWN

Early research funded by the Children’s Tumor Foundation has led to developments in schwannomatosis research. One award (2008) was for the development of the first mouse model for schwannomatosis with the same underlying gene mutations found in schwannomatosis patients. The second award (2011) was to support their use in a screening platform for schwannomatosis therapeutic agents.

The output of both studies contributed to the animal model generation. UCLA researchers have discovered that timing is everything when it comes to preventing a specific gene mutation (Smarcb1) in mice from developing rare and fast-growing cancerous tumors, called malignant rhabdoid tumors, which also affects young children. This mutation can also cause a benign tumor condition in humans in adulthood.

The scientists found that when one tumor suppressor gene is turned off or inactivated during early stages of a developing mouse embryo, it induces the formation of a malignant tumor. The research demonstrates that this type of malignant tumor will not form if the gene is inactivated during later stages of nerve development. However, when the gene is inactivated during later stages of nerve development and the Nf2 gene is also inactivated, benign tumors as the ones developed by schwannomatosis patients, develop in older mice.

The research, led by Dr. Marco Giovannini, a member of UCLA’s Jonsson Comprehensive Cancer Center and senior author of the study, is the first of its kind to analyze the functional role of mutations in a mouse model with both tumor suppressor genes known as SMARCB1 and NF2.

Read more about the study and the results in the UCLA Research Alert. The full article was published in Nature Communications, an open access journal that publishes high-quality research in biology, physics, chemistry, Earth sciences, and all related areas. Read the article here.

Close Menu